SOURCE: Generex Biotechnology

March 29, 2007 09:45 ET

Generex Biotechnology to Present Data at 4th International Symposium on Diabetes and Pregnancy

TORONTO -- (MARKET WIRE) -- March 29, 2007 -- Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it will be making two poster presentations at the 4th International Symposium on Diabetes and Pregnancy ( to be held in Istanbul, Turkey, March 29 - 31, 2007.

The Symposium is geared to specialists in diabetes, endocrinology, gynecology and obstetrics, perinatology, neonatology, basic scientists, pediatrics, midwives, nurses, nutritionists and dietitians.

The Company will be making the following poster presentations:

--  Near Normalization of Metabolic Control in Type-1 DM Using
    Conventional Insulin Therapy and a 13-Point Method Designed to Enhance
    Compliance, by Doctors Marco Guevara-Aguirre, Jaime Guevara-Aguirre, and
    Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito,
    Ecuador, and Dr. Gerald Bernstein, the Company's Vice-President for Medical
--  Metformin Gum: An Alternative Method for Delivery of Biguanides, by
    Doctors Marco Guevara-Aguirre, Jaime Guevara-Aguirre, and Jeannette
About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact Information

  • For more information, please contact:

    Shayne Gilliatt

    Andrew Hellman
    CEOcast, Inc.